3-(3-甲氧基苯基)-5-甲基-1,2-恶唑-4-羧酸乙酯 | 917388-43-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 3-(3-甲氧基苯基)-5-甲基-1,2-恶唑-4-羧酸乙酯
• 英文名称: Ethyl 3-(3-methoxyphenyl)-5-methylisoxazole-4-carboxylate
• 英文别名: ethyl 3-(3-methoxyphenyl)-5-methyl-1,2-oxazole-4-carboxylate
• CAS: 917388-43-3
• 化学式: C₁₄H₁₅NO₄
• 分子量: 261.277
• InChiKey: XFARCSDUCZCVHI-UHFFFAOYSA-N

物化性质

• 沸点：
  400.8±45.0 °C(Predicted)
• 密度：
  1.159±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  19
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  61.6
• 氢给体数：
  0
• 氢受体数：
  5

安全信息

• 海关编码：
  2934999090

反应信息

• 作为反应物：
  描述：

  3-(3-甲氧基苯基)-5-甲基-1,2-恶唑-4-羧酸乙酯 在 水 、 sodium hydroxide 作用下， 以 甲醇 为溶剂， 生成 3-(3-甲氧基苯基)-5-甲基-1,2-恶唑-4-羧酸
  参考文献：
  名称：

  Isoxazolopyridone derivatives as allosteric metabotropic glutamate receptor 7 antagonists

  摘要：

  This Letter describes the synthesis and evaluation of mGluR7 antagonists in the isoxazolopyridone series. In the course of modi. cation in this class, novel solid support synthesis of the isoxazolopyridone scaffold was developed. Subsequent chemical modi. cation led to the identification of several potent derivatives with improved physicochemical properties compared to a hit compound 1. Among these, 2 showed good oral bioavailability and brain penetrability, suggesting that 2 may be useful for in vivo study to elucidate the role of mGluR7. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.11.070
• 作为产物：
  描述：

  3-(1-吡咯烷基)巴豆酸乙酯 、 3-methoxybenzaldehyde oxime 在 吡啶 、 N-氯代丁二酰亚胺 、 三乙胺 作用下， 以 氯仿 为溶剂， 生成 3-(3-甲氧基苯基)-5-甲基-1,2-恶唑-4-羧酸乙酯
  参考文献：
  名称：

  Isoxazolopyridone derivatives as allosteric metabotropic glutamate receptor 7 antagonists

  摘要：

  This Letter describes the synthesis and evaluation of mGluR7 antagonists in the isoxazolopyridone series. In the course of modi. cation in this class, novel solid support synthesis of the isoxazolopyridone scaffold was developed. Subsequent chemical modi. cation led to the identification of several potent derivatives with improved physicochemical properties compared to a hit compound 1. Among these, 2 showed good oral bioavailability and brain penetrability, suggesting that 2 may be useful for in vivo study to elucidate the role of mGluR7. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.11.070

文献信息

• Acyl guanidines as beta-secretase inhibitors
  申请人：Gerritz Samuel

  公开号：US20070015754A1

  公开（公告）日：2007-01-18

  There is provided a series of substituted acyl guanidines of Formula (I) or a stereoisomer; or a pharmaceutically acceptable salt thereof, wherein R 1 , R 2 , R 3 , R 4 and R 5 as defined herein, their pharmaceutical compositions and methods of use. These compounds inhibit the processing of amyloid precursor protein (APP) by β-secretase and, more specifically, inhibit the production of Aβ-peptide. The present disclosure is directed to compounds useful in the treatment of neurological disorders related to β-amyloid production, such as Alzheimer's disease and other conditions affected by anti-amyloid activity.

  提供了一系列的取代酰基鸟氨酸化合物（I）或其立体异构体；或其药学上可接受的盐，其中R1、R2、R3、R4和R5如本文所定义，以及它们的药物组合物和使用方法。这些化合物抑制β-分泌酶对淀粉样前体蛋白（APP）的加工，更具体地抑制Aβ-肽的产生。本公开涉及用于治疗与β-淀粉样蛋白产生有关的神经系统疾病，例如阿尔茨海默病和其他受抗淀粉样蛋白活性影响的疾病的化合物。
• US7273882B2
  申请人：——

  公开号：US7273882B2

  公开（公告）日：2007-09-25
• US7612069B2
  申请人：——

  公开号：US7612069B2

  公开（公告）日：2009-11-03
• [EN] AMINOACETAMIDE ACYL GUANIDINES AS BETA-SECRETASE INHIBITORS<br/>[FR] GUANIDINES D'ACYLE ACETAMIDE AMINE EN TANT QU'INHIBITEURS DE BETA-SECRETASE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2007002220A2

  公开（公告）日：2007-01-04

  [EN] There is provided a series of substituted acyl guanidines of Formula (Ik) or a stereoisomer; or a pharmaceutically acceptable salt thereof, wherein R₂, R₃, R₄, R₅, R₂₅, R₂₆ and R₂₇ as defined herein, their pharmaceutical compositions and methods of use. These compounds inhibit the processing of amyloid precursor protein (APP) by ß-secretase and, more specifically, inhibit the production of Aß-peptide. The present disclosure is directed to compounds useful in the treatment of neurological disorders related to ß-amyloid production, such as Alzheimer's disease and other conditions affected by anti-amyloid activity.
  [FR] La présente invention a trait à une série de guanidines d'acyle substitués de formule (Ik), dans laquelle: R₂, R₃, R₄, R₅, R₂₅, R₂₆ et R₂₇ sont tels que définis dans la description, ou un stéréoisomère; ou un sel pharmaceutiquement acceptable de celles-ci; à leurs compositions pharmaceutiques et leurs procédés d'utilisation. Ces composés sont inhibiteurs du processus de la protéine précurseur d'amyloïde par la ß-sécrétase et, plus spécifiquement, inhibiteurs de la production de peptide Aß. La présente invention a également trait à des composés utiles dans le traitement de troubles neurologiques liés à la production de ß-amyloïde, tels que la maladie d'Alzheimer et d'autres conditions affectées par l'activité anti-amyloïde.
• Isoxazolopyridone derivatives as allosteric metabotropic glutamate receptor 7 antagonists
  作者：Masayuki Nakamura、Hideki Kurihara、Gentaroh Suzuki、Morihiro Mitsuya、Mitsuru Ohkubo、Hisashi Ohta

  DOI：10.1016/j.bmcl.2009.11.070

  日期：2010.1

  This Letter describes the synthesis and evaluation of mGluR7 antagonists in the isoxazolopyridone series. In the course of modi. cation in this class, novel solid support synthesis of the isoxazolopyridone scaffold was developed. Subsequent chemical modi. cation led to the identification of several potent derivatives with improved physicochemical properties compared to a hit compound 1. Among these, 2 showed good oral bioavailability and brain penetrability, suggesting that 2 may be useful for in vivo study to elucidate the role of mGluR7. (C) 2009 Elsevier Ltd. All rights reserved.